Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.READ MORE
Aranesp® is a proven option for patients with anemia due to CKD
patients received Aranesp®
during clinical trials1,*
patient-years
of experience2,†
*Cumulative estimate based on
subjects who received ≥ 1 dose (actual
exposure) for completed and ongoing (per protocol
randomization)
clinical
studies from launch through October 31, 2016.
†US exposure estimate methodology based on total monthly dollar
revenue,
assumed monthly
revenue per patient, assumed patient loss
rate, and
assumed route of administration
share
from 2002 through
November 30,
2017. It assumes an increase on the patient level, not
accounting for dose
increases, and does not reflect price increases
since 2008.
More than 95% of patients
on
dialysis had their Hb
successfully
maintained
with Aranesp®3,‡
‡Vanrenterghem et al, Kidney Int. 2002. Data from
a multicenter, randomized, open-label
study
comparing epoetin, given 1, 2, or 3 times weekly
IV or SC, with Aranesp®, at a
reduced dose
frequency, in dialysis patients (N = 522). Dose
adjustments were made as
necessary and per
study protocol to maintain individual patients’ Hb
within a target
range of –1.0 to +1.5 g/dL of their
baseline Hb and between 9 g/dL and 13 g/dL for up
to
52 weeks. The primary endpoint was the
change in Hb between baseline and the
evaluation
period at weeks 25 to 32 of treatment.
The mean change in Hb from baseline to the
evaluation period was similar in the Aranesp® and
epoetin groups, and the difference
between the
two treatment groups was 0.03 g/dL. This was
not a statistically significant
or clinically relevant
difference. 97% (178/183) of patients’ Hb levels
were
successfully maintained on Aranesp® QW or
less after conversion from epoetin during the
evaluation period.
Amgen sales support team
Your sales rep team and key account managers are
your source of
support for any
questions about
ordering or details about Aranesp®.
1-877-255-1114
Facility management tools
Obtain tools from your Amgen Sales Support Team to
help
your facility.
Coverage and reimbursement support
An Amgen Reimbursement Specialist can assist you
with insurance
verification,
co-pays, and reimbursement resources.
Reliability in supply is essential to Amgen
Since 2001, Amgen has consistently supplied
Aranesp®
to support patients.4,§
In the last 10 years, even in the wake of natural
disasters
and other
disruptive events, customers**
have not
experienced a supply shortage of
Aranesp®.4,5
§Based on 99.9% of product shipped to Amgen Authorized Distributors of Record only.
**US wholesalers only (data through April 17, 2017).
Learn more about Amgen manufacturing at
amgenbiotech.com
ANEMIAHUB.COM
Designed specifically for nephrology healthcare
professionals,
anemiahub.com
is your comprehensive source for anemia
management education.
Not an Anemia HubTM member? Register here
For nearly 30 years,
Amgen has
demonstrated
a commitment to the
nephrology community.
Important Safety Information including Boxed WARNINGS
Important Safety Information including Boxed WARNINGS